AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.
Gilead’s Yescarta - recently acquired through its purchase of Kite Pharma - has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
More than one third of patients referred by GPs to Weight Watchers in a bid to stave off diabetes saw their blood sugar levels return to normal, a study published in the British Medical Journal has found.
Award-winning playwright Simon Vinnicombe’s baby son George was just six months old when he fell gravely ill with a shock diagnosis of type 1 diabetes. He talks to PharmaTimes about life with the disease and his hopes for a cure
The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.
Business development director at Star, Ryan Wooller, discusses commercial outsourcing and how the company has adapted to provide the best solutions as pharma companies look to innovate and reduce costs
Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.